DK1963484T3 - Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf - Google Patents

Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf

Info

Publication number
DK1963484T3
DK1963484T3 DK06820577.2T DK06820577T DK1963484T3 DK 1963484 T3 DK1963484 T3 DK 1963484T3 DK 06820577 T DK06820577 T DK 06820577T DK 1963484 T3 DK1963484 T3 DK 1963484T3
Authority
DK
Denmark
Prior art keywords
applications
bacterial strains
producing raw
raw bacterial
producing
Prior art date
Application number
DK06820577.2T
Other languages
English (en)
Inventor
John Lawson Stanford
Cynthia Ann Stanford
Graham Mcintyre
Oscar Adelmo Bottasso
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Application granted granted Critical
Publication of DK1963484T3 publication Critical patent/DK1963484T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
DK06820577.2T 2005-12-21 2006-12-19 Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf DK1963484T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0526033.6A GB0526033D0 (en) 2005-12-21 2005-12-21 Method
PCT/GB2006/004780 WO2007071978A1 (en) 2005-12-21 2006-12-19 Method of producing rough strains of bacteria and uses thereof

Publications (1)

Publication Number Publication Date
DK1963484T3 true DK1963484T3 (da) 2011-09-19

Family

ID=35840894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06820577.2T DK1963484T3 (da) 2005-12-21 2006-12-19 Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf

Country Status (15)

Country Link
US (2) US8071354B2 (da)
EP (2) EP2298860A3 (da)
JP (1) JP5202330B2 (da)
CN (1) CN101384699B (da)
AT (1) ATE519838T1 (da)
AU (1) AU2006328209B2 (da)
BR (1) BRPI0620291B8 (da)
CA (1) CA2633127C (da)
DK (1) DK1963484T3 (da)
ES (1) ES2369569T3 (da)
GB (1) GB0526033D0 (da)
NZ (1) NZ568810A (da)
PL (1) PL1963484T3 (da)
SI (1) SI1963484T1 (da)
WO (1) WO2007071978A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201216800D0 (en) * 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
CN109414463A (zh) * 2016-02-25 2019-03-01 托马斯·朱利叶斯·波洛迪 治疗慢性传染性疾病的组合物和方法
CN109562155A (zh) * 2016-06-24 2019-04-02 艾普特沐恩生物股份有限公司 激活猪属动物的免疫系统的方法
CA3066189A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
US11077179B2 (en) * 2017-08-10 2021-08-03 Epicgenetics, Inc. Method for treating fibromyalgia and chronic fatigue syndrome
WO2020089488A1 (en) * 2018-11-02 2020-05-07 4D Pharma Research Limited Compositions comprising bacterial strains
WO2020115161A1 (en) 2018-12-04 2020-06-11 Sabiotec Spin-Off Sl Immunostimulant for use against pathogens
SG11202106258YA (en) 2018-12-12 2021-07-29 4D Pharma Res Ltd Compositions comprising parabacteroides bacterial strains for treating cancer
EP4043555A4 (en) * 2020-01-21 2023-01-18 Liaoning Greatest Bio-Pharmaceutical Co., Ltd. Use of rhodococcus ruber cell wall skeleton in regenerative medicine
GB202004007D0 (en) * 2020-03-19 2020-05-06 Immodulon Therapeutics Ltd Coronavirus

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1054055A (en) 1975-05-27 1979-05-08 Institut Armand-Frappier Isolation and characterization of phenotypes of mycobacteria
WO1991002562A1 (en) 1989-08-17 1991-03-07 Surgical Laser Products, Inc. Integral end structure for medical laser waveguide
GB8919321D0 (en) 1989-08-25 1989-10-11 Univ London Treatment of chronic inflammatory conditions
WO1992007621A1 (en) 1990-11-05 1992-05-14 Bsd Medical Corporation Urethral inserted applicator for prostate hyperthermia
ATE154759T1 (de) 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
US5521300A (en) 1991-08-13 1996-05-28 Norval B. Galloway Oligonucleotides complementary to mycobacterial nucleic acids
EP0592894B1 (en) 1992-10-13 2001-05-30 F. Hoffmann-La Roche Ag Oligonucleotides derived from the SOD family
US6136529A (en) 1993-09-03 2000-10-24 Gen-Probe Incorporated Nucleic acid probes to Mycobacterium avium complex
US5994346A (en) 1995-02-03 1999-11-30 Regents Of The University Of California Use of exochelins in the preservation of organs for transplant
US5786326A (en) 1995-02-03 1998-07-28 Horwitz; Lawrence D. Method for the treatment of atherosclerosis and vascular injury by prevention of vascular smooth muscle cell proliferation
US5721209A (en) 1995-02-03 1998-02-24 The Regents Of The University Of California Iron chelator and inhibitor of iron-mediated oxidant injury
JP4241929B2 (ja) 1996-05-22 2009-03-18 ジェン―プローブ・インコーポレーテッド Ｍｙｃｏｂａｃｔｅｒｉｕｍ Ｋａｎｓａｓｉｉを検出するための組成物および方法
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
GB9701897D0 (en) 1997-01-30 1997-03-19 Aqua Health Europ Ltd Vaccine
US7067500B2 (en) 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
DE19911208A1 (de) 1999-03-13 2000-09-14 Walther Carl Kurt Gmbh Steckkupplung zur Verbindung von Rohrleitungen, Schläuchen oder dergleichen
GB0025694D0 (en) 2000-10-19 2000-12-06 Univ London Vaccine
WO2004034961A2 (en) 2001-09-06 2004-04-29 Activbiotics, Inc. Antimicrobial agents and uses thereof
CA2465846A1 (en) 2001-11-21 2003-06-05 Activbiotics, Inc. Targeted therapeutics and uses thereof
AU2002364562A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Metal complexes and formulations of rifamycin analogues and uses therof
AU2002364162A1 (en) 2001-12-13 2003-06-30 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
AU2003209127A1 (en) 2002-02-11 2003-09-04 Auburn University High-sensitivity real-time polymerase chain reaction for detection of nucleic acids
WO2003101445A1 (en) 2002-06-03 2003-12-11 Activbiotics, Inc. Intravenous rifalazil formulation and methods of use thereof
EP1534330B8 (en) 2002-09-06 2014-06-04 UCL Business PLC Whole bacterial cells as immune modulator
AR046583A1 (es) 2003-11-14 2005-12-14 Ucl Biomedica Plc Uso de una composicion inmunomoduladora
US7442374B2 (en) 2004-07-19 2008-10-28 Ucl Biomedica Plc Composition for increasing the survival to slaughter rate of piglets
US7171940B2 (en) * 2004-12-27 2007-02-06 Federal-Mogul World Wide, Inc. Heat shield for engine mount

Also Published As

Publication number Publication date
EP2298860A3 (en) 2012-04-25
JP5202330B2 (ja) 2013-06-05
CA2633127A1 (en) 2007-06-28
ATE519838T1 (de) 2011-08-15
NZ568810A (en) 2011-09-30
AU2006328209A1 (en) 2007-06-28
BRPI0620291A2 (pt) 2011-11-08
ES2369569T8 (es) 2012-06-26
US20090304749A1 (en) 2009-12-10
EP1963484A1 (en) 2008-09-03
AU2006328209B2 (en) 2012-10-11
GB0526033D0 (en) 2006-02-01
US8512694B2 (en) 2013-08-20
BRPI0620291B1 (pt) 2020-12-15
BRPI0620291B8 (pt) 2021-05-25
EP2298860A2 (en) 2011-03-23
EP1963484B1 (en) 2011-08-10
JP2009520489A (ja) 2009-05-28
ES2369569T3 (es) 2011-12-02
CN101384699B (zh) 2012-10-10
PL1963484T3 (pl) 2012-08-31
WO2007071978A1 (en) 2007-06-28
US8071354B2 (en) 2011-12-06
SI1963484T1 (sl) 2012-06-29
US20120082699A1 (en) 2012-04-05
CN101384699A (zh) 2009-03-11
CA2633127C (en) 2015-08-04

Similar Documents

Publication Publication Date Title
DK1963484T3 (da) Fremgangsmåde til frembringelse af rå bakteriestammer og anvendelser heraf
WO2009158658A3 (en) Induction of flocculation in photosynthetic organisms
DK1856257T3 (da) Fremgangsmåder under anvendelser af oligonucleotid med dobbelt specificitet og oligonucleotid med dobbelt specificitet
WO2009068214A3 (de) Heteroaryl-substituierte piperidine
WO2007134294A3 (en) Novel chlorella species and uses therefor
DK2016169T3 (da) Solvent-tolerante mikroorganismer og fremgangsmåder til isolering
PH12015501581A1 (en) Method for using a bacillus subtilis strain to enhance animal health
ZA200801467B (en) Method of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
GB2463337A (en) Methods of producing organic products with photosynthetic organisms and products and compositions thereof
MX2008001652A (es) Copolimeros de poliamonio-polisiloxano.
DK1999160T3 (da) Acryleret hyaluronsyre
DE602006018709D1 (de) Estergebundene geminitensidverbindungen zur verwendung in der gentherapie
BRPI1010837A2 (pt) prevenção e tratamento de diarreia alérgica
MY149886A (en) Novel strains of lactobacillus helveticus
DE602008000176D1 (de) Verfahren zur Umwandlung von Glukose in Aniline durch Mikroorganismen
WO2018053451A8 (en) NEW PARATRANSGENIC SYSTEM FOR BIOLOGICAL CONTROL OF DISEASE TRANSMITTER MOSQUITOES
FR3050738B1 (fr) Microorganismes temoins de decontamination
MX2009004549A (es) Adhesivo de poliuretano.
WO2006032724A3 (en) Novel laccase enzymes and their uses
ATE434940T1 (de) Verfahren zur verbesserung der immunfunktion bei säugern unter verwendung von lactobacillus reuteri-stämmen
ATE491335T1 (de) Bakterielles produkt marinen ursprungs, das sich zur verhinderung des durch makroalgen und wirbellose meerestiere verursachten makro- und mikro-biofouling eignet
MY140061A (en) Improved method for the production of ramipril
DK1835021T3 (da) Ny stamme tildelt anti-sygdomsegenskaber mod værts- og bakteriel cellesammensætning
MY160112A (en) Use of a carbonaceous substitute for the production of yeasts
WO2006071746A3 (en) Engineered dopamine neurons and uses thereof